Statement of Principles concerning reactive arthritis (Balance of Probabilities) (No. 76 of 2018)

The instrument sets out several core legal‑medical concepts that decision‑makers must apply when assessing claims under the VEA or MRCA. Those concepts are defined primarily in section 7 and Schedule 1, and they are the functional building blocks of the causation test.

Reactive arthritis, as used in this Statement of Principles, is defined in subsection 7(2). The definition is multi‑part. It requires an immune‑mediated arthritis lasting more than four weeks. It ordinarily requires association with evidence of a preceding extra‑articular infection. It also expressly excludes a list of other specific conditions, namely acute rheumatic fever, certain viral arthritides that are part of the usual clinical spectrum (for example Ross River virus, Barmah Forest virus, rubella virus, parvovirus B19), leptospirosis, Lyme disease, post‑streptococcal reactive arthritis and septic arthritis (s 7(2)(a)-(c)(i)-(vi)). The instrument also notes typical clinical features in an editorial Note to s 7(2), including predominantly lower limb asymmetric oligoarthritis and possible extra‑articular manifestations.

The instrument references the ICD‑10‑AM classification, noting that reactive arthritis attracts code M02, but it makes explicit that for the purpose of this Statement of Principles the statutory definition in s 7(2) governs (ss 7(3)-(4)). This means administrative application must follow the textual definition in the instrument, not mere reliance on an ICD code.

A distinct concept is death from reactive arthritis. Subsection 7(5) treats reactive arthritis, in relation to a person, as including death from a terminal event or condition that was contributed to by the person’s reactive arthritis. The Schedule defines "terminal event" with examples such as pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function (Schedule 1, terminal event).

Causation is a two‑step concept in the instrument. Section 9 lists factors that must exist for connection on the balance of probabilities. Those factors are discrete and temporally bounded. Examples include: an "infection as specified" within three months before clinical onset (s 9(1)); HIV infection at the time of clinical onset (s 9(2)); hepatitis B vaccination within 30 days before clinical onset (s 9(3)); intravesical or intradermal BCG therapy within 30 days (s 9(4)); active mycobacterial disease within 30 days (s 9(5)); intestinal bypass surgery within one year (s 9(6)); and inability to obtain appropriate clinical management (s 9(7)). The Schedule defines "infection as specified" by three subcategories, including clinical or laboratory evidence of bowel infection, sexually acquired urogenital infection (excluding genital warts and herpes simplex), or infection with specific organisms such as Staphylococcus aureus and several Chlamydia species (Schedule 1, infection as specified).

The relationship to service concept is explicit in section 10. Section 10(1) requires that any factor from s 9 must be related to the person’s relevant service. The instrument defines "relevant service" in the Schedule as eligible war service, defence service (excluding operational, hazardous and British nuclear test defence service as specified), or peacetime service under the MRCA (Schedule 1, relevant service). Section 10(2) limits the application of s 9(7) (inability to obtain appropriate clinical management), making it applicable only to material contribution to, or aggravation of, reactive arthritis where the reactive arthritis pre‑existed or was contracted before or during, but did not arise out of, the relevant service.

Finally, section 11 creates a cross‑reference mechanism where a factor in s 9 refers to an injury or disease already the subject of another Statement of Principles under s 196B(3) of the VEA. In that circumstance, the factors in that other Statement apply according to their own terms. This is an explicit rule for coordinating multiple Statements.

Collectively, these concepts structure the evidentiary and temporal requirements for establishing that reactive arthritis, or death from it, is connected with relevant service on the balance of probabilities. The instrument supplies definitions for many terms in the Schedule, but it leaves a small number of terms (for example "appropriate clinical management") without a statutory definition, which is relevant to application.

This Statement of Principles affects three primary groups by name and effect. First, veterans and other persons making claims under the Veterans' Entitlements Act 1986 or the Military Rehabilitation and Compensation Act 2004 whose claims involve reactive arthritis or death from reactive arthritis are directly affected. The instrument states that it applies to a claim to which s 120B of the VEA or s 339 of the MRCA applies (s 5). Those statutory cross‑references identify the universe of claims in which decision‑makers must apply this Statement.

Second, decision‑makers and case officers within the Department or agency charged with administering the VEA and MRCA are affected because they must apply the definition, factors and relationship to service rules to assess whether reactive arthritis is "connected with the circumstances of a person's relevant service" on the balance of probabilities. The instrument is issued under subsection 196B(3) of the VEA, which is the statutory mechanism for the Repatriation Medical Authority to determine Statements of Principles used in adjudication of such claims (s 3).

Third, clinicians, medical assessors and experts who provide clinical or laboratory evidence for claims are affected in practice. The instrument specifies types of medical evidence that will be legally relevant, for example clinical or laboratory evidence of bowel infection or sexually acquired urogenital infection in support of the "infection as specified" factor (Schedule 1, infection as specified). Claimants and advisers will therefore be obliged to obtain and present records on infection, vaccination, surgical history, BCG therapy, HIV or active mycobacterial disease status, and evidence about clinical management access within the defined time windows (see s 9 and Schedule 1).

The instrument can also affect parties who hold records that are relevant to claims. For example, hospitals, clinics and Defence medical services that hold vaccination records, BCG therapy records, surgical records for intestinal bypass, or laboratory confirmations of infections will be sources of evidence needed to meet the temporal and diagnostic requirements set out in s 9 and Schedule 1.

The Statement also affects interlinked administrative instruments. Where a factor in s 9 refers to an injury or disease the subject of another Statement of Principles, that other Statement's factors are to be applied as in force from time to time (s 11). This creates an interdependence between this Statement and other Statements, affecting how multiple conditions are adjudicated in combined claims.

The instrument does not itself create entitlements, specify payment amounts, or set disciplinary or criminal penalties. It is an evidentiary framework to be applied in claims processes, and therefore its principal effect is to determine which medical facts and temporal relationships will operate to support or deny connection to relevant service.

The Statement of Principles imposes no direct statutory duties or civil rights by itself beyond its function as an evidentiary instrument. It does, however, establish legal thresholds that create practical rights and obligations in the adjudication of claims under the VEA and MRCA.

Rights created or clarified by the instrument are procedural and evidentiary. A person making a claim for reactive arthritis or death from reactive arthritis gains the right to have their claim assessed against the specific medical definition and enumerated factors in the instrument. If the claimant establishes, on the balance of probabilities, that at least one factor in s 9 existed and that the factor was related to the person’s relevant service (s 10(1)), then under the framework of claims adjudication that use Statements of Principles, the condition may be regarded as connected with service. The instrument records the Repatriation Medical Authority's view that reactive arthritis and death from it can be related to relevant service on the balance of probabilities (s 8). That view supplies the evidentiary presumption context within which rights to service connection are assessed.

Obligations for the parties deciding claims are implicit. Decision‑makers must apply the instrument's definition and factors when considering whether reactive arthritis is connected to relevant service. They must check whether at least one of the factors in s 9 is present and whether it is related to the person’s relevant service as defined in the Schedule (ss 9, 10). Where a factor refers to a different injury or disease that has its own Statement of Principles, the decision‑maker must apply the factors in that other Statement according to its terms (s 11).

The instrument creates practical evidentiary obligations for claimants. To meet the s 9 threshold, claimants will need to present clinical or laboratory evidence consistent with the instrument's defined factors. For example, "infection as specified" requires clinical or laboratory evidence of bowel infection, sexually acquired urogenital infection (excluding genital warts and herpes simplex), or infection with specified organisms (Schedule 1, infection as specified). Vaccination records, records of BCG therapy, documentation of intestinal bypass surgery and evidence of HIV or active mycobacterial disease timing are all matters that will typically be required to establish the temporal links in s 9(1)-(6).

There is a particular procedural limitation tied to s 9(7) (inability to obtain appropriate clinical management). Section 10(2) constrains the use of s 9(7) to cases where reactive arthritis was suffered or contracted before or during, but did not arise out of, relevant service. That means s 9(7) cannot be used to establish causation where reactive arthritis first arose out of the person’s service. The instrument thereby places a definitional duty on both claimants and decision‑makers to consider the timing and origin of the condition relative to service.

No enforcement powers, penalties, or sanctions are included in the instrument. The instrument is not itself a code of conduct or a penal provision. Its operative effect is to shape entitlement decisions made under the VEA and MRCA by providing a controlled list of medically‑relevant factors and definitions.

The Statement of Principles does not create criminal or civil penalties, nor does it itself contain enforcement mechanisms that impose sanctions. The instrument is silent on fines, imprisonment, administrative penalties, or enforcement processes. The Repatriation Medical Authority issues it under the statutory power in subsection 196B(3) of the Veterans' Entitlements Act 1986, which is the mechanism for determining Statements of Principles to be used in adjudicating claims under the VEA and MRCA (s 3). The instrument therefore functions as an evidentiary and causation reference, not as a stand‑alone enforcement instrument.

Enforcement in practice occurs indirectly through the claims administration processes under the VEA and MRCA. The instrument applies to claims to which s 120B of the VEA or s 339 of the MRCA applies (s 5). Those statutory schemes include their own decision, review and appeal mechanisms. Decision‑makers administering entitlement, compensation or rehabilitation under those Acts are required to apply Statements of Principles set by the Repatriation Medical Authority when assessing whether a condition is connected to relevant service. The instrument does not itself detail how decision‑makers must proceed, the standard operating procedures for disputes, or any penalty for non‑compliance by an administrative actor.

Because the instrument contains definitional and temporal elements, the practical "enforcement" effect is that decisions that do not apply the Statement of Principles correctly may be subject to remedy through the VEA and MRCA review and appeal pathways. The instrument does not specify those pathways, but it establishes the standards against which causal connection should be assessed.

The only explicit actions the instrument takes in relation to other instruments are repeal of the prior Statement of Principles No. 27 of 2010 (s 4) and the cross‑reference mechanism in s 11 that requires engagement with other Statements where a factor refers to another injury or disease. There is no explicit administrative penalty for failure to apply s 11; however, the cross‑reference is mandatory in textual terms.

The instrument identifies certain terms and thresholds that could give rise to interpretive disputes, for example what constitutes "appropriate clinical management" in s 9(7), and what it means for a factor to be "related to the relevant service" under s 10(1). Those interpretive issues are resolved through application in the claim decision process and, where necessary, review or appeal processes under the governing statutes. The instrument does not itself allocate enforcement discretion or set evidentiary procedures beyond the textual factors and defined terms.

The instrument is expressly created under subsection 196B(3) of the Veterans' Entitlements Act 1986 and is intended to be applied within the claims framework established by the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA) (see s 3 and s 5). It therefore operates as a subordinate legal instrument that provides medical causation criteria for the substantive schemes in those Acts. The instrument specifies that it applies to claims to which s 120B of the VEA or s 339 of the MRCA applies (s 5). Those cross‑references determine the statutory contexts in which this Statement of Principles is authoritative.

Section 11 provides a specific rule for interaction with other Statements of Principles made under subsection 196B(3) of the VEA. Where a factor in s 9 refers to an injury or disease that already has its own Statement of Principles, then "the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time" (s 11). This is an explicit coordination mechanism. Practically, it requires decision‑makers to consult and apply the diagnostic and temporal criteria contained in other Statements where relevant, rather than treating the factor in s 9 as self‑standing.

The instrument also interacts with medical classification standards by reference. It notes that reactive arthritis attracts ICD‑10‑AM code M02, and references the Tenth Edition, effective date 1 July 2017, of The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD‑10‑AM) (s 7(3)-(4)). However, it explicitly states that the meaning of reactive arthritis for applying the Statement of Principles is that given in subsection 7(2), so the textual statutory definition takes precedence over mere coding. The reference functions as a cross‑check rather than a replacement of the statutory definition.

The instrument's Schedule defines "relevant service" in terms that carve out particular categories under the VEA and MRCA, for example eligible war service other than operational service, defence service other than hazardous service and British nuclear test defence service, and peacetime service under the MRCA (Schedule 1, relevant service). Those definitions integrate the Statement into the broader statutory definitions of service used under the VEA and MRCA. The instrument does not alter those underlying definitions; it uses them to set the boundary of its application.

The instrument does not purport to alter entitlement rules, compensation schedules, rehabilitation obligations or administrative review procedures contained in the VEA or MRCA. It is confined to medical causation criteria. Any operational interaction with other laws occurs through the claims processes governed by those Acts, which will apply this instrument as the medical evidence standard for reactive arthritis causation.

Finally, the instrument repeals the previous Statement of Principles concerning reactive arthritis No. 27 of 2010 (s 4). That repeal is the direct statutory interaction with earlier subordinate law. It means that from the commencement date the 2010 Statement no longer governs causation for reactive arthritis in the relevant claim contexts, and decision‑makers must apply this 2018 Statement in its stead.

This instrument records a single explicit amendment action in its own terms, being the repeal of an earlier Statement of Principles. Section 4 states that the Statement of Principles concerning reactive arthritis No. 27 of 2010 (Federal Register of Legislation No. F2010L01043) made under subsection 196B(3) of the VEA is repealed. The instrument itself is dated 24 August 2018, and its commencement date is 24 September 2018 (see the header and s 2). Those are the dates relevant to the instrument's life cycle as recorded in the text.

No later amendments, variations, or revocations are recorded within the instrument. The instrument does, however, contain a mechanism for interaction with other Statements of Principles "as in force from time to time" (s 11). That phrase anticipates that other Statements may be updated, and it requires application of those other Statements' factors as they stand when invoked. The instrument therefore operates within a dynamic statutory environment where related Statements may be amended independently. This text does not record any such subsequent changes.

The Schedule contains definitions that define various terms for the instrument's operation. The text does not include transitional provisions other than the repeal of the 2010 Statement. It also contains a Note indicating the ICD‑10‑AM edition and effective date to which it refers (s 7(4)). The instrument provides no review clause, expiry date, or automatic amendment mechanism.

For the purposes of tracing amendment history, the following points are recorded in the instrument and are the only express amendment‑related steps present in the text:

• The Repatriation Medical Authority affixed its Common Seal to the instrument and signed it as dated 24 August 2018 (header material and signature block).

• The instrument repealed the 2010 Statement of Principles for reactive arthritis, as stated in s 4.

• The instrument commenced on 24 September 2018, one month after the date on the instrument (s 2).

Beyond those entries, no amendments, corrigenda, or subsequent amendments are included in this instrument text.

The instrument itself contains no litigation history, and it names no cases or judicial decisions. It is a statutory medical‑evidentiary instrument, not a judicial opinion or legislative explanatory memorandum. The text includes the Repatriation Medical Authority's statement of view about the medical‑scientific evidence (s 8), but it does not reference any court proceedings, tribunal decisions or precedents.

Because the instrument functions as a determinative evidentiary standard to be used by decision‑makers under the VEA and MRCA, disputes over its application could generate administrative review or litigation under those Acts. However, no such disputes, appeals or judicial outcomes are recorded or referenced in the instrument itself. Where claimants or decision‑makers disagree about the application of this Statement of Principles to a particular person, the relevant statutory review, reconsideration and appeal mechanisms in the VEA and MRCA would govern any contested outcomes. Those procedures and any litigation emerging from them are outside the scope of this instrument's text and are not described in it.

The instrument’s silence as to litigation history means analysts should rely on administrative records and external sources to determine whether particular applications of the Statement have been the subject of review or judicial scrutiny. That information is not contained in this document.

The instrument contains several textual features and defined limitations that create discrete risks of error or misunderstanding when it is applied in claims. These "gotchas" are matters of wording, timing, definition scope and cross‑references that advisers and decision‑makers must be alert to.

1. Definition controls over ICD code. The instrument mentions ICD‑10‑AM code M02 as the code that reactive arthritis attracts (s 7(3)), and it cites the ICD edition (s 7(4)). However the instrument also explicitly instructs that in applying the Statement of Principles the meaning of reactive arthritis is that given in subsection 7(2), not merely the ICD code (s 7(3)). In practice this means that a diagnosis labelled M02 in medical records must still be tested against the statutory definition in s 7(2), including the listed exclusions. Treat code alone as insufficient.

2. Narrow temporal windows. The factors in s 9 contain short, specific time windows. For example: "infection as specified" must be within three months before clinical onset (s 9(1)); hepatitis B vaccination, intravesical or intradermal BCG therapy, and active mycobacterial disease each have 30‑day windows before clinical onset (ss 9(3)-(5)); intestinal bypass surgery has a one‑year window (s 9(6)). Evidence that either falls outside the relevant window will not, on the face of the instrument, satisfy the s 9 factor.

3. Exclusions from "infection as specified". The Schedule defines "infection as specified" and includes clinical or laboratory evidence of bowel infection, sexually acquired urogenital infection (including proctitis and excluding genital warts and herpes simplex), or infection with Staphylococcus aureus or specific Chlamydia species (Schedule 1). That definition both includes and excludes conditions. For sexually acquired infections, claims involving genital warts or herpes simplex will not qualify under s 9(1). Read the Schedule carefully.

4. Narrow scope of s 9(7) inability to obtain appropriate clinical management. Section 10(2) limits the application of the s 9(7) factor to cases where the reactive arthritis was suffered or contracted before or during, but did not arise out of, the relevant service. That prevents reliance on healthcare access failures to establish causation where the condition first arose out of service. Moreover, "appropriate clinical management" is not defined in the Schedule. This undefined term creates interpretive risk and potential dispute over what evidence will meet s 9(7).

5. Excluded diagnoses. Subsection 7(2)(c) lists specific exclusions, including acute rheumatic fever, a set of viral arthritides (Ross River virus, Barmah Forest virus, rubella, parvovirus B19), leptospirosis, Lyme disease, post‑streptococcal reactive arthritis and septic arthritis. These exclusions are dispositive for the Statement. A claimant diagnosed with one of those excluded conditions cannot rely on this Statement of Principles for reactive arthritis connection.

6. Relationship to service requirement. Even if a s 9 factor exists in the required temporal window, s 10(1) requires that the factor be related to the person’s relevant service. The Schedule defines "relevant service" with carve outs for certain service types (Schedule 1, relevant service). A factor arising from non‑relevant service will not satisfy the instrument.

7. Cross‑reference complexity. Section 11 requires application of other Statements of Principles where a s 9 factor refers to another injury or disease covered by a different Statement. Practitioners must identify and consult those other Statements "as in force from time to time", which can introduce complexity and an evidentiary chain to satisfy causation.

8. Death claims: contributory death. Subsection 7(5) includes death from a terminal event or condition that was contributed to by the person’s reactive arthritis. Claimants must therefore present evidence that reactive arthritis materially contributed to a terminal event listed or of similar nature. The Schedule's examples of terminal events are illustrative, but causation to death requires evidence of contribution.

9. Absence of procedural detail. The instrument sets the medical criteria but does not provide procedural instructions for how decision‑makers should gather or weigh evidence, nor does it define some key terms such as "appropriate clinical management" or "related to the relevant service". Those lacunae are points at which interpretive disputes can arise.

10. Repeal of 2010 Statement. The earlier 2010 Statement is repealed (s 4). Practitioners must ensure they use the 2018 Statement for claims with relevant dates after commencement, and be careful with claims that straddle the repeal/commencement boundary, because the instrument does not include transitional provisions.

Each of these points is grounded in the text of the instrument and can materially affect the outcome of claims if not handled properly.

Compliance in this context means preparing or adjudicating a claim for reactive arthritis or death from reactive arthritis in a way that aligns with the textual requirements of the Statement. The steps below are directly tied to the instrument’s provisions and the Schedule definitions.

1. Establish that the claim falls within the instrument’s application. Confirm that the claim is one to which s 120B of the VEA or s 339 of the MRCA applies (s 5). Check the claimant’s service against the instrument’s definition of "relevant service" in the Schedule to ensure the claimant’s service type is within the specified categories (Schedule 1, relevant service).

2. Confirm the diagnosis against s 7(2). Obtain medical records that demonstrate an immune‑mediated arthritis lasting more than four weeks, and show any evidence of a preceding extra‑articular infection if available. Verify that the diagnosis is not an excluded condition listed in s 7(2)(c). Treat any ICD‑10‑AM code M02 entry as a prompt to test the underlying diagnostic facts against s 7(2), because the instrument requires application of that subsection’s meaning (s 7(3)).

3. Identify at least one s 9 factor within the required time window. For each factor in s 9 the claimant wishes to rely upon, obtain documentary evidence that meets the instrument’s timing and substance requirements:

• For s 9(1) infection as specified within three months before clinical onset, obtain clinical notes or laboratory reports showing bowel infection, sexually acquired urogenital infection (including proctitis and excluding genital warts and herpes simplex) or laboratory confirmation of infection with Staphylococcus aureus, Chlamydia pneumoniae, Chlamydia psittaci, or Chlamydia trachomatis (Schedule 1).

• For s 9(2) HIV infection at the time of clinical onset, obtain contemporaneous serology or clinical records confirming HIV status dated to the time of onset.

• For s 9(3) hepatitis B vaccination within 30 days before clinical onset, obtain vaccination records showing date and vaccine type.

• For s 9(4) intravesical or intradermal BCG therapy within 30 days before clinical onset, obtain oncological treatment records specifying BCG therapy and date.

• For s 9(5) active mycobacterial disease within 30 days before onset, obtain microbiology, imaging or clinical documentation confirming active mycobacterial disease as defined in the Schedule.

• For s 9(6) intestinal bypass surgery within one year before onset, obtain surgical discharge summaries and operation notes.

• For s 9(7) inability to obtain appropriate clinical management, assemble evidence of attempts to obtain care, applicable service health policies at the time, and contemporaneous records that show denial, lack of access, or insufficient management. Remember s 10(2) limits use of s 9(7) to cases where the condition pre‑existed or was contracted before or during, but did not arise out of, the relevant service.

4. Establish the relationship to relevant service. For any s 9 factor shown on the evidence, the claimant must show that the factor was related to relevant service per s 10(1). That will typically require contemporaneous service medical records, deployment or occupational exposure records, or other documentary material linking the infection, vaccination, therapy, surgery or inability to obtain management to the period of relevant service.

5. If a s 9 factor refers to another Statement of Principles, obtain and apply that Statement. Section 11 requires that where a s 9 factor refers to an injury or disease covered by another Statement of Principles, the factors in that other Statement apply. Identify any such cross‑reference and obtain the current text of that other Statement, then secure the supporting evidence required by it.

6. Address death claims appropriately. If the claim is for death from reactive arthritis, obtain evidence that the terminal event or condition was contributed to by reactive arthritis. Use the Schedule’s definition of "terminal event" as guidance for types of events typically considered, but be prepared to link clinical deterioration to the reactive arthritis with medical expert evidence if necessary (s 7(5) and Schedule 1).

7. Prepare for interpretive issues. For terms not defined in the Schedule, particularly "appropriate clinical management", gather robust factual evidence about the care environment, standards at the time, and any administrative or logistical barriers. Decision‑makers will need to evaluate what was "appropriate" in context.

8. Consider timing and transition. The instrument repealed the 2010 Statement (s 4) and commenced on 24 September 2018 (s 2). For claims spanning the repeal date, document the timing carefully, and be prepared to show which Statement applies to which period or events.

9. Use medical experts where necessary. Because the Statement requires clinical and temporal linkages, use treating clinicians and independent medical experts to interpret records and attest to onset dates, the plausibility of temporal links, and the role of reactive arthritis in a terminal event if applicable.

10. Keep records of all source documents. The statute depends on documentary proof: vaccination records, laboratory reports, surgery records, service medical records and hospital discharge summaries are central. For infections the Schedule requires clinical or laboratory evidence, so an unsigned note may be insufficient without corroborating lab results or contemporaneous clinical documentation.

Following these concrete steps aligns claim preparation and adjudication with the text of the Statement of Principles and minimises the risk of a decision failing to engage with one of the instrument’s key textual requirements.